A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer.
Zlotocha
Sarah
S
Genitourinary Oncology Group at University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA.
Staab
Mary Jane
MJ
Horvath
Dorothy
D
Straus
Jane
J
Dobratz
Jeanne
J
Oliver
Katherine
K
Wasielewski
Stephine
S
Alberti
Dona
D
Liu
Glenn
G
Wilding
George
G
Eickhoff
Jens
J
McNeel
Douglas G
DG
D000135:Acid Phosphatase; D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000096:biosynthesis; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D016898:Interferon-alpha; D019444:Vaccines, DNA; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases